EUVIMEDEUVIMED entdecken
Crossref

New therapeutic targets for the management of moderate-severe psoriasis

José C. Ruiz-Carrascosa, Angela Ayén-Rodriguez, José M. Llamas-Molina, Ricardo Ruiz-Villaverde

Journal of IMIDs · 2022

DOI: 10.24875/jimids.m21000016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of IMIDs, 2022. Verfasst von José C. Ruiz-Carrascosa und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The field of moderate-severe psoriasis is experiencing a real therapeutic revolution in recent years with the appearance of new molecules that present more selective pathophysiological targets.The incorporation of biosimilar drugs with less clinical development than the original brands may result in the incorporation of new molecules with better levels of efficacy and safety being relegated to the background.In the present review, we review the main anti-IL-17, anti-IL-23, and JAKi drugs that have been incorporated and will soon be incorporated into our therapeutic arsenal, making special mention of their efficacy, safety, and persistence characteristics as deduced from the main pivotal clinical trials and series of real clinical practice.

Zitieren

APA

Ruiz-Carrascosa, J. C., Ayén-Rodriguez, A., Llamas-Molina, J. M., & Ruiz-Villaverde, R. (2022). New therapeutic targets for the management of moderate-severe psoriasis. Journal of IMIDs. https://doi.org/10.24875/jimids.m21000016

Vancouver

Ruiz-Carrascosa JC, Ayén-Rodriguez A, Llamas-Molina JM, Ruiz-Villaverde R. New therapeutic targets for the management of moderate-severe psoriasis. Journal of IMIDs. 2022. doi:10.24875/jimids.m21000016

BibTeX
@article{RuizCarrascosa2022,
  author = {Ruiz-Carrascosa, José C. and Ayén-Rodriguez, Angela and Llamas-Molina, José M. and Ruiz-Villaverde, Ricardo},
  title = {New therapeutic targets for the management of moderate-severe psoriasis},
  journal = {Journal of IMIDs},
  year = {2022},
  doi = {10.24875/jimids.m21000016}
}
Kostenlos starten →